Alzamend Neuro, Inc. — Director's Dealing 2021

Jun 15, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Alzamend Neuro, Inc. (ALZN)
CIK: 0001677077
Period of Report: 2021-06-14

Reporting Person: Katzoff David J (N/A)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	18000	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Warrants	$3.00	2024-04-15	Common Stock (9000)		Direct
Stock Options (Right to Buy)	$1.00	2029-01-20	Common Stock (400000)		Direct
Stock Options (Right to Buy)	$1.50	2029-10-31	Common Stock (850000)		Direct
Stock Options (Right to Buy)	$1.50	2029-11-25	Common Stock (250000)		Direct
Stock Options (Right to Buy)	$1.50	2029-11-25	Common Stock (1000000)		Direct

Footnotes

F1: Vests ratably over forty-eight (48) months commencing after January 20, 2019.

F2: Vests quarterly over sixteen (16) quarters commencing after October 31, 2019.

F3: Vests quarterly over sixteen (16) quarter commencing after November 25, 2019.

F4: Vests based upon certain performance criteria. Of these options, none shares of Common Stock are vested and exercisable.